Short-Term Residential Drug Treatment: 28-Day and 30-Day Programs

Short-term residential drug treatment programs — most commonly structured as 28-day or 30-day stays — represent one of the most widely recognized formats in the US addiction treatment system. This page covers how these programs are defined by federal and accreditation standards, how their clinical structure operates across phases, the populations for whom this level of care is typically indicated, and the boundaries that distinguish short-term residential treatment from adjacent levels of care. Understanding the structure and limitations of this format is essential for anyone researching the landscape of drug rehab program types.

Definition and scope

Short-term residential treatment is a time-limited, 24-hour live-in treatment model typically spanning 28 to 30 days, though programs ranging from 21 to 45 days are also classified within this category depending on payer and licensing standards. The Substance Abuse and Mental Health Services Administration (SAMHSA) classifies short-term residential treatment as a distinct service type within its National Survey of Substance Abuse Treatment Services (N-SSATS), which SAMHSA publishes annually to document the national inventory of treatment facilities.

Under the American Society of Addiction Medicine (ASAM) Patient Placement Criteria — the dominant clinical framework used by treatment providers and insurers across the United States — short-term residential care maps primarily to Level 3.5 (Clinically Managed High-Intensity Residential Services). This level requires clinically managed, 24-hour-a-day services with trained counseling staff available at all times, though Level 3.5 does not require continuous physician presence in the same manner as a medically managed intensive inpatient unit (Level 4). The ASAM criteria and levels of care framework underpins most insurance-based coverage determinations for this type of program.

The 28-day model specifically traces its widespread adoption to the Minnesota Model of chemical dependency treatment developed in the 1950s at Willmar State Hospital and Hazelden, which structured treatment around roughly one month of residential care followed by community-based support. That historical design has since been formalized into reimbursement and licensing structures at the state level across all 50 jurisdictions, making the 28-to-30-day window the de facto standard for what insurers and regulators recognize as "short-term residential."

How it works

Short-term residential programs operate through a sequenced clinical structure. While exact phasing varies by facility and accreditation body, the standard operational model follows these discrete stages:

1. Intake and assessment — Upon admission, staff conduct a biopsychosocial assessment and substance use disorder evaluation to establish a diagnosis and treatment plan. This typically includes medical screening, psychiatric evaluation for co-occurring disorders, and ASAM criteria placement scoring.
2. Medical stabilization / detoxification — If the patient requires supervised withdrawal, medically supervised detox services are provided either on-site or through a coordinated referral prior to or at the start of residential enrollment.
3. Primary treatment phase — The core residential period delivers individual therapy, group therapy, psychoeducation, and — where clinically indicated — medication-assisted treatment. Evidence-based modalities such as cognitive behavioral therapy are standard elements under Joint Commission and CARF accreditation standards.
4. Discharge planning and aftercare coordination — The final phase, beginning no later than mid-stay under most accreditation guidelines, establishes a continuing care plan. This may include connection to intensive outpatient programs, sober living arrangements, or relapse prevention planning.

Facilities operating as SAMHSA-certified treatment programs are required to maintain individualized treatment plans that are reviewed and updated at defined intervals — typically every 7 to 14 days for residential settings, per SAMHSA Treatment Improvement Protocol (TIP) standards. The Joint Commission and CARF accreditation standards impose additional documentation, safety, and staffing requirements that are enforced through on-site surveys.

Common scenarios

Short-term residential treatment is clinically indicated across a range of presentations. The following represent the most frequently documented admission profiles in SAMHSA's National Survey of Substance Abuse Treatment Services data:

• Opioid use disorder — Patients stabilized on buprenorphine/Suboxone or naltrexone/Vivitrol who require a structured residential environment to establish medication adherence, coping skills, and relapse prevention habits.
• Alcohol use disorder — Individuals who have completed acute medical detoxification (typically 3–7 days) and require continued residential support to address behavioral and psychological dimensions of alcohol dependence. See alcohol rehab vs. drug rehab for classification distinctions.
• Stimulant use disorder — Patients with cocaine or methamphetamine dependence, for whom no FDA-approved pharmacotherapy exists, often benefit from the intensive behavioral intervention density that residential programs provide. More information appears on the stimulant addiction treatment reference page.
• Co-occurring disorders — Individuals with a concurrent mental health diagnosis, such as major depressive disorder or PTSD alongside a substance use disorder, where dual-track treatment is clinically indicated. The co-occurring disorders and dual diagnosis page documents assessment frameworks for this population.
• Prior outpatient failure — Patients who did not achieve or sustain remission through outpatient care and who present with sufficient severity to meet ASAM Level 3.5 criteria.

Decision boundaries

Short-term residential treatment occupies a specific position within the continuum of care and is not clinically appropriate for all presentations. Distinguishing it from adjacent levels requires applying defined criteria:

Short-term residential vs. long-term residential — Long-term residential treatment typically spans 6 to 12 months and is indicated for patients with severe social instability, chronic relapse history, or criminal justice involvement requiring extended therapeutic community exposure. Short-term programs of 28–30 days are designed for patients who retain greater baseline psychosocial stability and do not require the extended environmental restructuring of a therapeutic community model.

Short-term residential vs. partial hospitalization — Partial hospitalization programs (PHPs) deliver 20 or more hours of structured clinical services per week in a non-residential setting. PHPs are appropriate for patients who have stable, supportive living environments; short-term residential is indicated when the home environment itself constitutes a risk factor or when 24-hour supervision is clinically necessary.

Short-term residential vs. intensive outpatient — Intensive outpatient programs require a minimum of 9 hours of structured services per week under SAMHSA IOP standards. Short-term residential care delivers substantially higher service density and is not interchangeable with IOP for patients meeting ASAM Level 3.5 criteria.

A critical limiting factor of the 28-to-30-day format is that the timeline does not align with the neurobiological duration of substance-related brain adaptation. The National Institute on Drug Abuse (NIDA), in its Principles of Drug Addiction Treatment: A Research-Based Guide (3rd edition), states that research indicates treatment durations of less than 90 days are of limited effectiveness for most patients, and that longer durations produce better outcomes. The 28-day model therefore functions most effectively as one phase of a longer continuum — not a standalone episode — with robust aftercare and continuing care planning as a clinical necessity, not an optional add-on. Coverage eligibility for continued care following residential discharge is governed in part by requirements under the Affordable Care Act rehab requirements and drug rehab insurance coverage frameworks.

References

• SAMHSA National Survey of Substance Abuse Treatment Services (N-SSATS)
• SAMHSA Treatment Improvement Protocols (TIPs)
• NIDA: Principles of Drug Addiction Treatment: A Research-Based Guide, 3rd Ed.
• ASAM Patient Placement Criteria / ASAM Criteria
• The Joint Commission: Behavioral Health Care Accreditation
• CARF International: Behavioral Health Standards
• SAMHSA: Find Treatment / Program Locator